Blood Cancers | Tumor

Ryoncil Receives FDA Approval for Children With GVHD

December 18th 2024, 10:45pm

Article

This marks the first mesenchymal stromal cell therapy approved by the FDA for children with acute graft versus host disease.

Pregnancy-Associated Hematological Malignancies Linked With Complications

November 29th 2024, 4:00pm

Article

Researchers have found an increased frequency of severe maternal morbidity and obstetric complications among women who received a diagnosis of a hematological malignancy during pregnancy.

Identifying Cardiovascular Disease Risk in Cancer Survivors

October 22nd 2024, 9:00pm

Article

The risk of cardiovascular disease is elevated in cancer survivors, regardless of treatment, and is influenced by cancer type and treatment-related factors.

Education on MPN Symptoms, Treatments Leads to Greater Involvement in Care

October 3rd 2024, 7:00pm

Article

An expert explained the importance of education and involvement in care for patients with myeloproliferative neoplasms.

Reblozyl May Be ‘The Standard of Care’ Now in Lower-Risk MDS, Anemia

September 24th 2024, 3:00pm

Article

An expert discussed the findings of the COMMANDS trial evaluating Reblozyl’s role in red blood cell transfusion independence for patients with MDS.

In a World of Rushing, Cancer Taught Me to Slow Down

September 20th 2024, 5:00pm

Article

With my myelodysplastic syndrome and age, I find it hard to keep up; however, cancer and fatigue have taught me to live at my own pace.

Patients With Lower-Risk Myelofibrosis May Respond to Jakafi

September 18th 2024, 9:00pm

Article

Although Jakafi has been approved for patients with higher-risk myelofibrosis, those with lower-risk disease may also benefit from this treatment.

Why Transfusion Independence Matters for Patients With MDS

September 18th 2024, 7:00pm

Article

An expert explained the burden that red blood cell transfusions can place on patients with MDS.

Patient Characteristics Guide Decision Making for JAK Inhibitors in Myelofibrosis

September 9th 2024, 3:00pm

Video

Spleen size, blood counts and symptom burden are some of the factors cancer teams take into account when selecting which of the four JAK inhibitors to treat patient with myelofibrosis.

My Worries About Being Old as an MDS Survivor

September 6th 2024, 5:00pm

Article

Having myelodysplastic syndromes has taught me to cherish every day and to pursue the things that matter to me, like publishing a book I’ve been writing.